EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mono‐ TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study

Xue Yin iD, Na Deng, Jinglong Chen, Xiaoyan Ding

Cancer Medicine · 2025

DOI: 10.1002/cam4.70711 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Xue Yin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Phenylurea Compounds, Liver Neoplasms, Quinolines. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Capital's Funds for Health Improvement and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lenvatinib (LEN) is the recommended first‐line therapy for unresectable hepatocellular carcinoma (uHCC), but resistance frequently develops, and limited data exist on second‐line treatments. This study evaluated the efficacy and safety with a focus on the sorafenib (SOR) or regorafenib (REG)‐ based monotherapy or combination therapy in patients with uHCC after failure of first‐line LEN.

Methods

Patients with first‐line LEN failure between May 2018 and December 2023 were retrospectively collected. Based on second‐line regimens, 70 patients were divided into two groups: the TKI group ( n = 21) and the TKI‐ICI group ( n = 49). Overall survival (OS) and progression‐free survival (PFS) were analyzed by Kaplan–Meier methods, and multivariate analysis was performed to identify prognostic factors.

Results

In the TKI‐ICI group, median PFS was 5.27 months and median OS was 12.53 months. In the TKI group, median PFS was 3.10 months and median OS was 7.50 months. The objective response rate (ORR) was 19.1% in the TKI group and 16.3% in the TKI‐ICI group. The disease control rate (DCR) was 85.7% in the TKI‐ICI group and 61.9% in the TKI group. In the TKI‐ICI cohort, multivariable Cox analysis revealed the high albumin to neutrophil ratio index (ANRI) was an independent predictor for PFS, while alpha‐fetoprotein > 400 ng/mL was the independent predictor for OS. Safety profiles in both cohorts showed manageable toxicity, with no treatment‐related deaths.

Conclusions

The combination of TKI and ICI presents a promising second‐line treatment option after LEN failure, regardless of the specific second‐line TKI used.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularPhenylurea CompoundsLiver NeoplasmsQuinolinesProtein Kinase InhibitorsAntineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedSorafenibDisease ProgressionAdultPyridinesAged, 80 and overProgression-Free Survival

Stichwörter der Autor:innen

Lenvatinibhepatocellular carcinomaimmune checkpoint inhibitorsecond‐line therapytyrosine kinase inhibitor

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesProtein Kinase InhibitorsSorafenibregorafenibImmune Checkpoint InhibitorsPyridines

Autor:innen und Institutionen

  • Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Xue Yin

Förderung

  • Capital's Funds for Health Improvement and Research

Zitieren

APA

Yin, X., Deng, N., Chen, J., & Ding, X. (2025). Mono‐ TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.70711

Vancouver

Yin X, Deng N, Chen J, Ding X. Mono‐ TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study. Cancer Medicine. 2025. doi:10.1002/cam4.70711

BibTeX
@article{Yin2025,
  author = {Yin, Xue and Deng, Na and Chen, Jinglong and Ding, Xiaoyan},
  title = {Mono‐ TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70711}
}
Kostenlos starten →